Generated July 2026 from current fund data.
Overview
DIVO and XYLD are both monthly-paying equity ETFs that use covered call options to generate income, but they target different underlying universes. DIVO invests in a basket of dividend-paying stocks curated by Amplify and sells calls against them, aiming for income alongside capital growth. XYLD replicates the S&P 500 and systematically writes calls on the full index, prioritizing current yield above all else.
How they differ
The biggest difference is the underlying exposure: DIVO holds a filtered basket of dividend stocks, while XYLD tracks the entire S&P 500. That distinction drives their yield profiles—XYLD distributes at 10.00% against DIVO's 4.73%, a gap that reflects how aggressively XYLD monetizes its call premium versus how conservatively DIVO manages income relative to its dividend-stock foundation.
DIVO's lower beta (0.56 vs. XYLD's 0.41) and smaller expense ratio differential (0.56% vs. 0.60%) suggests DIVO carries meaningfully more equity market sensitivity, likely because it holds individual dividend payers without the dampening effect of full-index diversification. Inception dates also differ—XYLD has operated since mid-2013 with longer track record data, while DIVO launched in late 2016.
The call-writing mechanics matter too. XYLD's high yield signals consistent, systematic call sales across all 500 constituents; DIVO's lower yield indicates either less aggressive call writing, more dividend income flowing through untouched, or both. Both funds charge similarly low fees, so strategy, not cost, is the primary differentiator.
Who each is best for
DIVO: Fits investors who want core exposure to quality dividend stocks with partial call-income enhancement—those comfortable with moderate downside capture (beta ~0.56) in exchange for a reasonable yield cushion that doesn't sacrifice as much upside participation.
XYLD: Fits investors seeking maximum current income from broad-market equity exposure and willing to accept a lower beta (0.41) and capped upside in exchange for a 10% distribution yield; suits those building an income-focused sleeve and less concerned with capital appreciation.
Key risks to know
- High-yield NAV erosion in XYLD: A 10.00% distribution yield on a $40.84 price will erode NAV if the underlying S&P 500 return (before option premium) falls short of that payout, particularly over multi-year periods. At that level of distribution, return-of-capital treatment becomes material.
- Call-writing cap on upside in both: During strong equity rallies, covered calls limit gains; XYLD's systematic, index-wide approach means it forgoes outsized moves proportionally across all holdings, while DIVO's basket approach may miss concentrated outperformers.
- Dividend-stock concentration risk in DIVO: A curated basket of dividend payers introduces sector and individual-stock concentration compared to XYLD's index breadth; dividend cuts or faltering dividend growers can crimp income stability.
- Systematic call roll risk: Both funds continuously write and roll options; if volatility dries up or call premiums compress, income may decline even if the underlying assets perform well.
- Beta divergence and downside participation: XYLD's 0.41 beta suggests protective positioning that may lag in rising markets but also limits losses in downturns; DIVO's higher 0.56 beta means closer tracking of dividend-stock price swings.
Bottom line
XYLD prioritizes yield through aggressive call monetization on a diversified index base; DIVO balances income with growth through a more conservative call strategy on dividend-filtered stocks. If you value maximum current income and can tolerate capped upside, XYLD's 10% yield and lower beta stand out; if you prefer steadier dividend flow with higher growth potential, DIVO's 4.73% yield and higher beta may align better. Past performance of covered call strategies during different market regimes doesn't guarantee future distributions.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.